3U01AG061173-04S1 |
2022 |
$311482 |
Optimization of microtubule-stabilizing triazolopyrimidines as therapeutics for Alzheimer's disease and related tauopathies |
5U01AG061173-04 |
2022 |
$746084 |
Optimization of microtubule-stabilizing triazolopyrimidines as therapeutics for Alzheimer's disease and related tauopathies |
5U01AG061173-03 |
2021 |
$851784 |
Optimization of microtubule-stabilizing triazolopyrimidines as therapeutics for Alzheimer's disease and related tauopathies |
3U01AG061173-03S1 |
2021 |
$159949 |
Optimization of microtubule-stabilizing triazolopyrimidines as therapeutics for Alzheimer's disease and related tauopathies |
5U01AG061173-02 |
2020 |
$946116 |
Optimization of microtubule-stabilizing triazolopyrimidines as therapeutics for Alzheimer's disease and related tauopathies |
1U01AG061173-01 |
2019 |
$948369 |
Optimization of microtubule-stabilizing triazolopyrimidines as therapeutics for Alzheimer's disease and related tauopathies |